Mr. Londoner is a capital markets and capital architecture expert and a senior life science executive. Having started his career as a research analyst for J. & W. Seligman & Co., Inc., a leading institutional money management firm in New York City, NY, he quickly found himself at the forefront of the biotech industry in the early 1990s, leading him to manage $3.5 billion in mutual and pension funds and international assets.
His passion for medical innovation led him to co-found, govern and bring to the public market a number of life science companies, including BioSig Technologies, Inc. [Nasdaq:BSGM]. Working in close collaboration with key opinion leaders in electrophysiology, BioSig aims to improve the outcomes of cardiac ablations for the treatment of arrhythmias through novel technological solutions developed by the company, and further apply its core competency in advanced biomedical signal processing and analysis to other areas of medicine.
His prior experience in recognizing the early potential of biotech led Londoner to form the Alliance for Advancing Bioelectronic Medicine, an independent non-profit network of professionals dedicated to innovation at the intersection of healthcare and technology. The Alliance aims to increase awareness of bioelectronic medicine and build a platform for collaboration among stakeholders. Over the last decade, Londoner formed top level relationships with a number of medical centers of excellence such as Mayo Clinic, NYU Langone Hospital and UCLA, as well as other stakeholders, including investment communities, intellectual property experts and supply chain partners.
What is Kenneth L. Londoner's net worth?
The estimated net worth of Kenneth L. Londoner is at least $323,884.60 as of June 12th, 2023. Mr. Londoner owns 249,142 shares of BioSig Technologies stock worth more than $323,885 as of April 25th. This net worth evaluation does not reflect any other investments that Mr. Londoner may own. Learn More about Kenneth L. Londoner's net worth.
How do I contact Kenneth L. Londoner?
Has Kenneth L. Londoner been buying or selling shares of BioSig Technologies?
Kenneth L. Londoner has not been actively trading shares of BioSig Technologies during the last ninety days. Most recently, on Monday, June 12th, Kenneth L. Londoner bought 600 shares of BioSig Technologies stock. The stock was acquired at an average cost of $11.70 per share, with a total value of $7,020.00. Following the completion of the transaction, the chief executive officer now directly owns 249,142 shares of the company's stock, valued at $2,914,961.40. Learn More on Kenneth L. Londoner's trading history.
Who are BioSig Technologies' active insiders?
Are insiders buying or selling shares of BioSig Technologies?
During the last twelve months, BioSig Technologies insiders bought shares 1 times. They purchased a total of 600 shares worth more than $7,020.00. The most recent insider tranaction occured on June, 12th when CEO Kenneth L Londoner bought 600 shares worth more than $7,020.00. Insiders at BioSig Technologies own 9.3% of the company.
Learn More about insider trades at BioSig Technologies. Information on this page was last updated on 6/12/2023.
